Autologous stem cell transplant remains a backbone of MM treatment in medically fit patients, but our findings suggest that ASCT and lymphopenia-inducing therapies in MM have a largely irrecoverable effect on the CD4+ T cell population. This evidence concerns the gene CD4 and Miyoshi myopathy.